

PR#: 7956 Deviation No.:D-2020-0429

Record Status: Closed-Done

基本信息 General Information

□ Division: Innovent Biologics (Su Zhou) Co., Ltd

发起人 Originator: 吴, 洪健(PID-000204) 发起日期 Date Opened: 2020.12.26

简短描述 Short Description:

M1b DS2 细胞计数仪软件登陆不进去故障Failure to log in to the cell counter software

到期日期 Date Due: 2021.01.29 关闭日期 Date Closed: 2021.01.26

偏差信息 Deviation Information

发现人 Discovery By:孙磊20000433发现日期 Discovery On:2020.12.25汇报人Report By:吴洪健20000011汇报日期 Report On:2020.12.25

发生部门 Occurred Department: M1b DS2 汇报部门 Report Department: M1b DS2

偏差描述 Deviation Description:

2020.12.25 18:16在25D08细胞培养间生产DS2011009批次的贝伐珠单抗注射液M1b 3000L原液时,生产人员(20000433)按照《贝伐珠单抗注射液M1b 3000L原液细胞培养及收获批生产记录》(BPR100320-08)要求,在准备对样品DS2011009-3000L-D0细胞液取样测试前,准备细胞计数仪(MFG-M1b3-120)时,在打开细胞计数仪(MFG-M1b3-120)的软件Vi-Cell XR时,发Vi-Cell XR无法打开,并提示check sum error in the above system file. The application will terminate信息,提示信息见附件一,联系厂家工程师后,确认名称为VCsystem4文件出现损坏,故发起偏差。

描述的附件 Description attachment: 附件一:软件登录不进去提示信息.jpg

是否及时上报? Reporting in Time?: Yes

未及时上报的理由 Reason for not in Time:

NA

已采取的即时措施 Immediately Action Taken:

12/26/2020 07:37 PM (GMT+8:00) added by 洪健 吴 (PID-000204):

及时措施2、

行动项内容:将损坏的VCsystem4用备份的VCsystem4替换掉,并对细胞计数仪MFG-M1b3-120的部分账户根据历史提交的《用户账户创建/变更》表格,重新创建账户,用于生产使用,具体见附件三 《用户账户创建/变更》和附件四 :细胞计数仪MFG-M1b3-120工作日志。

完成部门: MST 完成日期: 2020.12.25

12/26/2020 01:36 PM (GMT+8:00) added by 洪健 吴 (PID-000204):

及时措施1、

行动项内容:用种子扩增间25C04的细胞计数仪MFG-M1b3-119对DS2011009-3000L-D0进行计数 , 计数结果:活细胞密

度: 0.848*106个/ml,细胞活率100%。见附件二 DS2011009-3000L-D0细胞液检测记录和结果。

完成部门: 生产部 完成日期: 2020.12.25

及时措施2、

行动项内容:将损坏的VCsystem4用备份的VCsystem4替换掉,并对细胞计数仪MFG-M1b3-120的部分账户根据历史提交的《用户账

户创建/变更》表格,重新创建账户,用于生产使用,具体见附件三《用户账户创建/变更》。

完成部门: MST 完成日期: 2020.12.25

即时措施附件 Immediately Action Attachment:

附件二 DS2011009-3000L-D0细胞液检测记录和结果.docx



PR#: 7956 Deviation No.:D-2020-0429

Record Status: Closed-Done 附件三 用户账户创建变更.docx

附件四:细胞计数仪MFG-M1b3-120工作日志.jpg

厂房设施名称 Facility Name: 产品所属阶段 Product Phase:

M1b Commercial

初步影响/风险评估Initial Impact/Risk Assessment

产品影响评估 Product Impact Assessment:

细胞培养间(25D08)的细胞计数仪(MFG-M1b3-120)Vi-Cell XR软件出现问题无法登陆后,采取即时措施:用种子扩增间(25C04)的细胞计数仪MFG-M1b3-119对DS2011009-3000L-D0样品进行计数 , 种子扩增间(25C04)的细胞计数仪MFG-M1b3-119的验证状态在有效期内,见附件五 细胞计数仪MFG-M1b3-119计量验证信息。

计数结果:活细胞密度:0.848*10^6个/ml,细胞活率100%,符合《贝伐珠单抗注射液M1b3000L细胞培养工艺规程》 (PFD00096-06)活细胞密度在0.7~1.1×10^6个/ml范围内的要求,因此,本偏差对DS2011009批次的3000L流加培养液无影响。

生产/检测的影响评估 Production/Testing Impact Assessment:

对细胞计数仪(MFG-M1b3-120)后续生产检测的影响评估在偏差的第二阶段调查总结/根本原因分析中说明。

其他影响评估描述 Other Impact Assessment Description:

对于细胞计数仪(MFG-M1b3-120)的验证状态、数据完整性问题在偏差的第二阶段调查总结/根本原因分析中说明。

初步影响评估附件 Initial Impact Assessment Attachment:

附件五细胞计数仪MFG-M1b3-119计量验证信息.jpg

偏差分级 Deviation Classification

偏差严重性 Deviation Severity:

1.细胞培养间(25D08)的细胞计数仪(MFG-M1b3-120)软件出现问题无法登陆后,采取即时措施用种子扩增间(25C04)的细胞计数仪MFG-M1b3-119对DS2011009-3000L-D0样品进行计数,计数结果符合《贝伐珠单抗注射液M1b 3000L细胞培养工艺规程》范围要求,因此本偏差对DS2011009 批次的3000L流加培养液无影响。2. 对细胞计数仪(MFG-M1b3-120)后续生产检测的影响评估、验证状态、数据完整性问题在偏差的第二阶段进行进一步调查。

偏差发生率 Reoccurrence Probability of Deviation:

过去12个月未发生类似缺陷(搜索关键词:M1b,细胞计数仪,登陆)

偏差分级 Deviation Classification: Minor

分级的理由 Reason for Classification:

12/28/2020 10:42 AM (GMT+8:00) added by 怡菁 王 (PID-000230):

该偏差对产品质量未造成影响,且过去12个月未发生类似缺陷,故定义为次要偏差。

是否需要调查? Investigation Required?: Yes

主调查人 Lead investigator: 王, 凯

不需要调查的理由 Reason for not Investigation:

调查总结&根本原因分析 Investigation & RCA

调查总结 Investigation Summary:

偏差简述:2020.12.25 18:16在25D08细胞培养间生产DS2011009批次的贝伐珠单抗注射液M1b 3000L原液时,生产人员(20000433)按照《贝伐珠单抗注射液M1b 3000L原液细胞培养及收获批生产记录》(BPR100320 08)要求,在准备对样品DS2011009 3000L D0细胞液取样测试前,准备细胞计数仪(MFG M1b3 120)时,在打开细胞计数仪(MFG M1b3 120)的软件Vi Cell XR时,发现Vi Cell XR无法打开,并提示check sum error in the above system file. The application will terminate信息,联系厂家工程师后,确认名称为VCsystem4文件出现损坏,故发起偏差。

原因调查:此次偏差从人员、设备、物料、方法、环境几个方面进行调查,形成附件6鱼骨图。

人员

人员资质:



PR#: 7956 Deviation No.:D-2020-0429

Record Status: Closed-Done

2020.12.25操作人员(20000433)和复核人员(20000808)在生产前已完成《贝伐珠单抗注射液M1b 3000L原液细胞培养及收获批生产记录》(BPR100320-07)和《M1b车间细胞计数仪使用、清洁与维护标准操作规程》(SOP200530)的培训;并且操作人员(20000433)和复核人员(20000808)具备细胞培养的岗位技能,已取得细胞培养上岗证,复核人员(20000808)已经具备SPV上岗证。

2020.12.25 偏差发生后由员工(05020003、05020015)在种子扩增间(25C04)完成细胞计数,二人在生产前均已完成《贝伐珠单抗注射液M1b 3000L原液细胞培养及收获批生产记录》(BPR100320-07)和《M1b车间细胞计数仪使用、清洁与维护标准操作规程》(SOP200530)的培训,具备细胞培养的岗位技能,且已取得细胞培养上岗证。

2020.12.28 MST员工(05080036)在执行2020.12.25偏差发生后的即时措施,员工(20000433)负责复核,MST员工(05080036)负责MST上游工作,已取得生产技术细胞培养工程师上岗证。

2020.12.28偏差发生后由生产人员(20000223)及员工(20000011)在种子扩增间(25C04)进行了细胞计数操作,二人在生产前均已完成《贝伐珠单抗注射液M1b 3000L原液细胞培养及收获批生产记录》(BPR100320-07)和《M1b车间细胞计数仪使用、清洁与维护标准操作规程》(SOP200530)的培训,具备细胞培养的岗位技能,且已取得细胞培养上岗证。

以上相关人员资质证明详见附件13。

人员操作:

2020.12.25员工(20000433、20000808)按照《M1b车间细胞计数仪使用、清洁与维护标准操作规程》(SOP200530)及《贝伐珠单抗注射液M1b 3000L原液细胞培养及收获批生产记录》(BPR100320-07)3000L流加培养2.5.10步骤执行细胞计数工作,计数前执行了细胞计数仪确认,设备状态无异常;在准备对样品DS2011009 3000L D0细胞液取样测试前,打开细胞计数仪(MFG M1b3 120)的软件Vi Cell XR时,发现Vi Cell XR无法打开,并提示check sum error in the above system file. The application will terminate信息。

2020.12.25发生异常之后即时措施之一:由生产部员工(05020003)及员工(05020015)用种子扩增间(25C04)的细胞计数仪MFG M1b3 119对DS2011009-3000L-D0进行计数的操作,计数过程及结果无异常,结果符合工艺规程要求。

2020.12.28 MST员工(05080036)执行2020.12.25偏差发生后即时措施即新建用户信息,员工(20000433)进行复核。期间员工(20000433)由于忘记密码而重置密码,更改密码后尝试登录软件 Vi Cell XR时,发现Vi Cell XR无法打开,并提示check sum error in the above system file. The application will terminate信息,出现与2020.12.25偏差发生时相同的现象。

2020.12.28 发生异常之后生产人员 (20000233、20000011) 用种子扩增间(25C04)的细胞计数仪MFG M1b3

119对DS2011009-3000L-D3进行计数操作,计数过程及结果无异常,结果符合工艺规程要求。

小结:人员资质和操作未发现异常,与本次偏差无关。

设备

设备状态检查:

生产前对细胞计数仪进行状态检查确认,设备于2020.06.17完成PM,下次PM时间为2021.04.22,设备PM状态正常。

2020.06.17~2020.12.25本次偏差发生时未出现关于本设备的偏差或变更,偏差发生前一直正常使用。

2020.12.25及2020.12.28细胞计数仪两次异常情况发生时,生产操作人员均按照流程执行使用前清洁确认,设备清洁状态无异常。

小结:细胞计数仪设备PM状态及清洁状态正常。

物料:

本次偏差不涉及物料。

方法:

查阅《M1b车间细胞计数仪使用、清洁与维护标准操作规程》(SOP200530)文件对设备使用、样品准备、试剂包更换、数据备份、清洁维护、注意事项、再验证等方面进行了详细的规定,现场操作人员也能严格按照文件要求执行生产操作。

文件编写符合《文件管理规程》(SMP00064),对生产操作的指导性良好,文件内容及规定流程符合要求,不是导致本次偏差的原因。小结:《M1b车间细胞计数仪使用、清洁与维护标准操作规程》(SOP200530)内容及流程规定清晰明确,未发现直接导致本次偏差的描述内容,目前文件规定流程较合理,不是本次偏差发生的直接原因。

扩展调查

密码设置

2020.12.25偏差发生后,MST员工(05080036)与供应商沟通后采用原始VCsystem4文件替换已损坏文件,并复建部分账户,2020.12.26~2020.12.27由已创建账户人员(20000011、20000016、20000317)执行细胞计数仪操作,没有出现异常。

2020.12.26-2020.12.27员工(20000433)未输入正确密码(此时密码为管理员新建账户时初始密码,未包含特殊字符),未登陆成功,没有更改密码操作,也没有执行细胞计数操作(执行了复核操作)。具体详见附件7 Vi cell细胞计数仪使用日志。

2020.12.28 厂家工程师进入现场,协助进行问题调查及解决,2020.12.28下午14:07,在MST员工(05080036)复建部分员工信息(2020.12.25发生偏差后制定的即时措施之一)时,员工(20000433)更改了自己账户密码(如前述,本次更改密码原因为忘记密码),之后尝试登录软件时,出现与2020.12.25相同check sum类型error。

随即厂家工程师重新复建用户(2020.12.28 15:29),发现新建账户后,员工(20000433)登录时(15:39)又发生"check sum error in the above system file. The application will terminate",如附件8报错说明所示,之后软件无法登录。

2020.12.28 15:39分之后供应商又重新复建账户,员工(20000433)登录时又重复发生上述错误2次(15:41和15:43)。具体记录见附件9审计追踪截图所示。

经询问员工(20000433)了解到,该员工密码中含有字符"~"。之后,该员工(2000043)更改密码(不含特殊字符),后即可正常登录。之后软件恢复正常,其他复建账户的员工可正常登录并使用。如附件10审计追踪截图2所示。



PR#: 7956 Deviation No.:D-2020-0429

Record Status: Closed-Done

查阅《Vi-Cell XR - Instruction For Use (IFU)》(page92、114),详见附件14,对于用户名及密码设置有如下描述:

按照上述描述,密码中不能含有: "/{}~|" 等5个特殊字符。

回顾2020.12.25偏差发生时现象及审计追踪文件,2020.12.25 下午16:52,员工(20000433)由于密码到期更改密码,经确认更改后的密码含有特殊字符,在此之后出现软件无法登录问题。如附件11审计追踪截图3

2020.12.28下午14:07,员工(20000433)重置密码(如前所述,发生在MST复建部分账户信息时,该员工更改了自己账户密码),之后就出现软件无法登录。如下图所示,与该员工沟通,确认重置的密码中也含有特殊字符"~"。如附件12审计追踪截图4

综上所属,可确定,本次偏差直接原因是员工(20000433)设置的密码中包含了 "~" 特殊字符,导致软件出现check sum类型error,进而软件无法登陆。

查阅《M1b车间细胞计数仪使用、清洁与维护标准操作规程》(SOP200530)以及相同设备的其他操作规程《细胞计数仪(Vi-Cell)使用、清洁及维护保养标准操作规程》(SOP200619, PD部门),《BECKMAN Vi-CELL XR细胞计数仪使用及维护保养标准操作规程》(SOP200426,QC部门),《BECKMAN Vi-CELL XR细胞计数仪使用及维护保养标准操作规程(MFG)》

(SOP200231, M1a),上述细胞计数仪相关文件均按照文件编写要求,对操作、清洁、维护等进行较详细的规定,而对密码设置方面没有进行规定,因此认为文件对密码设置方面的疏漏,导致员工无法获知密码设置具体要求,是本次偏差发生的根本原因。

相同设备扩展调查:

经调查《细胞计数仪(Vi-Cell)使用、清洁及维护保养标准操作规程》(SOP200619, PD部门),《BECKMAN Vi-CELL XR细胞计数仪使用及维护保养标准操作规程》(SOP200426, QC部门),《BECKMAN Vi-CELL XR细胞计数仪使用及维护保养标准操作规程(MFG)》(SOP200231, M1a)使用以上设备的其他部门员工账户密码未包含"/{}~|"特殊字符。

目前未出现人员由于设置5个特殊字符的密码"/{}~|"而导致软件无法打开的现象。

小结:员工密码设置时包含了不被允许的特殊字符,导致软件出现check sum类型error,进而软件无法登陆,是本次偏差发生的直接原因。

《M1b车间细胞计数仪使用、清洁与维护标准操作规程》(SOP200530)未对密码设置中不能含有:"/{}~|"等5个特殊字符进行描述,是导致本次偏差的根本原因。

环谙·

生产期间,细胞培养间及种子扩增间无EMS报警,满足生产需求,生产环境正常,本次偏差不涉及环境方面影响。

小结:环境条件正常,符合生产要求,未发现异常。

根本原因分析Root Cause Analysis

据上所述,员工密码设置时包含了不被允许的特殊字符"/{}~|",导致软件出现check sum类型error,进而软件无法登陆,是本次偏差发生的直接原因。

详细调查报告参见附件15 D-2020-0429偏差调查报告及影响评估

《M1b车间细胞计数仪使用、清洁与维护标准操作规程》(SOP200530)未对密码设置中不能含有:"/{}~|"等5个特殊字符进行描述,是导致本次偏差的根本原因。

调查附件 Investigation Attachments:

附件11 审计追踪截图3.png

附件6 鱼骨图.png

附件8 报错说明.jpg

附件12 审计追踪截图4.png

附件7 Vi cell细胞计数仪使用日志.png

附件9审计追踪截图.png

附件10 审计追踪截图2.png

附件14 Instruction for use Vi-cell XR.pdf

附件13 上岗证扫描件.pdf

根本原因分析 Root Cause Analysis:

员工密码设置时包含了不被允许的特殊字符"/{}~|",导致软件出现check sum类型error,进而软件无法登陆,是本次偏差发生的直接原因。

《M1b车间细胞计数仪使用、清洁与维护标准操作规程》(SOP200530)未对密码设置中不能含有:"/{}~|"等5个特殊字符进行描述,是导致本次偏差的根本原因。

针对根本原因采取的CAPA措施:

1、升级《M1b车间细胞计数仪使用、清洁与维护标准操作规程》(SOP200530)及相同设备其他操作规程(《细胞计数



PR#: 7956 Deviation No.:D-2020-0429

Record Status: Closed-Done

仪(Vi-Cell)使用、清洁及维护保养标准操作规程》(SOP200619, PD部门),《BECKMAN Vi-CELL XR细胞计数仪使用及维护保养标准操作规程》(SOP200426, QC部门),《BECKMAN Vi-CELL XR细胞计数仪使用及维护保养标准操作规程(MFG)》

(SOP200231, M1a)),增加关于密码设置注意事项:密码设置中不能含有: "/{}~|"等5个特殊字符。

根本原因分析附件 Root Cause Analysis Attachment:

原因描述 Cause Description:

《M1b车间细胞计数仪使用、清洁与维护标准操作规程》(SOP200530)未对密码设置中不能含有:"/{}~|"等5个特殊字符进行

描述,是导致本次偏差的根本原因。

原因分类 Cause Category 原因子分类 Cause Sub-Category 原因归属部门 Cause Department

Method/procedure Lack of procedure M1b DS2

缺陷描述 Defect Description:

细胞计数仪(MFG-M1b3-120)的软件Vi-Cell XR无法打开,登陆故障。

Facility/Utility/Equipment/Instrument Computerized System Settings & Validation

是否是重复偏差 Repeat Deviation?: No

判定重复偏差的原因 Justification for Repeat Deviation: 过去12个月未发生相同根本原因导致的偏差,故不是重复偏差。

重复偏差的原因描述 Reason of Repeat Deviation Description:

NA

相关的重复偏差 Repeat Deviation Records

PR# deviation# 简短描述 Short Description Record Status

最终影响/风险评估 Final Impact/Risk Assessment

对产品质量的影响 Impact on Product Quality:

本次偏差发生后(2020.12.25及2020.12.28),生产人员(05020003、2000233)用种子扩增间25C04的细胞计数仪MFG M1b3 119对DS2011009-3000L样品(分别为D0和D3样品)批次进行计数,结果符合工艺规程要求,与历史批次数据对比无显著偏离,本次偏差对该批次生产无影响、不影响产品质量

对其他批次的影响 Impact on Other Batches:

对其他批次无影响

对系统/设备的影响 Impact on System/Equipment:

本偏差对系统/设备无影响

对验证状态的影响 Impact on Validation State:

本次偏差是由于设置密码时包含了特殊字符,引起VCsystem4(文件包含创建的用户信息)包含不被软件接受的字符,软件启动需校验该文件,校验时即出现check sum类型报错,本次偏差仅影响到了已创建的用户信息,如附件15用户信息列表20201225及附件16用户信息列表20201230,对细胞计数仪IOQ(IOQ00170)及补充验证方案(CSVR00071)中涉及的其他功能无影响。不影响细胞计数仪的验证状态。新建账户后,用户其他功能如上所述,均正常使用,无异常情况出现。

对产品注册的影响 Impact on Product Registration:

本偏差对产品注册无影响

对法规符合性的影响 Impact on Regulation Compliance:

This report was generated by 鹏云 徐 on 2021.06.17 08:23AM in Timezone GMT+08:00

Page 5 of 10



PR#: 7956 Deviation No.:D-2020-0429

Record Status: Closed-Done

软件恢复后,查看结果数据以及审计追踪等,自2019.04.22安装后的验证数据或检测数据均完整(包含数据名称、测试者、测试时间以及结果等内容)如附件17 审计追踪及结果数据,未受到影响,无数据完整性问题,本偏差对法规符合性、数据完整性无影响

对稳定性的影响 Impact on Stability:

本偏差不影响产品稳定性

对其他方面的影响 Impact on Other Aspects:

软件恢复后,查看结果数据以及审计追踪等,自2019.04.22安装后的验证数据或检测数据均完整(包含数据名称、测试者、测试时间以及结果等内容),未受到影响,详见附件12审计追踪及结果数据,无数据完整性问题。

种子扩增间环境为C级背景,物品是由低级别(细胞培养间D级)至高级别(种子扩增间C级),样品转移时,按照《M1b生产区物品转移标准管理规程》(SMP00286)中由低级别向高级别转移的规定执行,对种子扩增间环境影响较小,同时由于摇瓶及摇床相对密闭,偏差发生后的计数没有打开摇床及摇瓶操作,不影响种子扩增间其他批次的生产。

受影响的部门 Impact Departments:

PD

M1b DS2

M1b DS1

QC1

M1a DS

影响/风险评估附件 Impact/Risk Assessment Attachment:

附件16 用户信息列表20201230.png

附件15 用户信息列表20201225.png

附件17 审计追踪及结果数据.pdf

受影响的产品信息 Impacted Product Information

产品最终处置建议 Product Disposition Proposal:

本次偏差发生后生产人员用种子扩增间25C04的细胞计数仪MFG M1b3 119对DS2011009-3000L样品批次进行计数,结果符合工艺规程要求,与历史批次数据对比无显著偏离,本次偏差对该批次生产无影响,不影响产品放行。

产品名称 Product Name: 贝伐珠单抗注射液M1b 3001L原液(商业化)

产品代码 Product Code

DS30-305

产品批号 Batch No.:

数量 Quantity

处理决定 Disposition

DS2011009

3000L

Release

受影响的物料信息 Impacted Material Information

物料名称 Material Name:

受影响的溶液信息 Impacted Media/Buffer Information

溶液名称 Media/Buffer Name:



PR#: 7956 Deviation No.:D-2020-0429

Record Status: Closed-Done

受影响的设备信息 Impacted Equipment Information

设备名称 Equipment Name: 细胞计数仪 设备代码 Equipment Code MFG-M1b3-120

偏差处理措施 Deviation Action Items

PR#:

责任人 Assigned To: 部门 Department:

截止日期 Date Due: 完成日期 Completed Date:

确认人 Verified By: 确认日期 Verified On:

行动项详细描述 Action Description:

纠正信息 Correction Information

PR#:

责任人 Assigned To: 部门 Department:

截止日期 Date Due:完成日期 Completed Date:确认人 Verified By:确认日期 Verified On:

行动项详细描述 Action Description:

纠正与预防措施 CAPA

PR#: 9002

责任人 Assigned To: 吴, 洪健(PID-000204) 部门 Department: M1b DS2

截止日期 Date Due: 2021.03.15 行动项详细描述 Action Description:

升级《M1b车间细胞计数仪使用、清洁与维护标准操作规程》(SOP200530),增加密码设置注意事项,不能含有: "/{}

~|" 等5个特殊字符。

PR#: 9024

责任人 Assigned To: 吕, 伟(PID-000039) 部门 Department: PD

截止日期 Date Due: 2021.03.15 行动项详细描述 Action Description:

《细胞计数仪(Vi-Cell)使用、清洁及维护保养标准操作规程》(SOP200619,PD部门)增加密码设置注意事项,不能含

有: "/{}~|" 等5个特殊字符

PR#: 9025

<u>责任人 Assigned To: 叶, 林(PID-000059)</u> <u>部门 Department:</u> M1a DS



PR#: 7956 Deviation No.:D-2020-0429

Record Status: Closed-Done

截止日期 Date Due: 2021.03.15 行动项详细描述 Action Description:

《BECKMAN Vi-CELL XR细胞计数仪使用及维护保养标准操作规程(MFG)》(SOP200231, M1a),增加密码设置注意事

项,不能含有: "/{}~|" 等5个特殊字符。

PR#: 9026

责任人 Assigned To: 支, 大雨(PID-000021) 部门 Department: QC1

截止日期 Date Due: 2021.03.15 行动项详细描述 Action Description:

《BECKMAN Vi-CELL XR细胞计数仪使用及维护保养标准操作规程》(SOP200426, QC部门),增加密码设置注意事项,不

能含有: "/{}~|" 等5个特殊字符

附件 File Attachments

关联记录 Reference Records

PR# Record Type 简短描述 Short Description Record Status 6835 Permanent Change Control M1b贝伐珠单抗注射液3000L原液工艺变更 Change control of M1b Bevacizumab injection 3000L in M1b 相关子记录 Related children	DD#	Posard Type	答句性法 Short Description	Pagard Status				
6835 Permanent Change Control M1b贝伐珠单抗注射液3000L原液工艺变更 Pending Change Eva. Post Change control of M1b Bevacizumab	相关子记录 Related children							
		7.	M1b贝伐珠单抗注射液3000L原液工艺变更 Change control of M1b Bevacizumab	Record Status Pending Change Eva. Post Ir				

PR# 8056	Record Type Investigation Task	简短描述 Short Description D-2020-0429+CSV+计算机系统影响 从计算机 软硬件方向调查本次偏差 investgate this deviation from hardware and software	Record Status Closed-Cancelled
9001	CAPA	由偏差D-2020-0429触发的CAPA CAPA from D-2020-0429	Pending Effectiveness Check



PR#: 7956 Deviation No.:D-2020-0429

Record Status: Closed-Done

Initial Approval				
QA Initial Review				
Area QA Initial Reviewed By:	赵, 琰	Area QA Initial Reviewed On:	2020.12.26 1	19:48
Classify Completed By:	王, 怡菁	Classify Completed On:	2020.12.28 1	10:52
Department Initial Review				
Department Leader 1 Reviewed By:	邓, 献存	Department Leader 1 Reviewed On:	2020.12.28 1	13:41
Department Leader 2 Reviewed By:		Department Leader 2 Reviewed On:		
Department Leader 3 Reviewed By:		Department Leader 3 Reviewed On:		
Department Leader 4 Reviewed By:		Department Leader 4 Reviewed On:		
Department Leader 5 Reviewed By:		Department Leader 5 Reviewed On:		
Area QA Leader Reviewed By:	王, 沛芳	Area QA Leader Reviewed On:	2020.12.28 1	13:04
Quality Initial Approval				
Quality Approver 1 Approved By:	管, 国兴	Quality Approver 1 Approved On:	2020.12.28 1	17:28
Quality Approver 2 Approved By:		Quality Approver 2 Approved On:		
Quality Approver 3 Approved By:		Quality Approver 3 Approved On:		
Final Approval				
QA Final Review				
QA Final Reviewed By:	王, 怡菁	QA Final Reviewed On:	2021.01.25 1	13:22
Investigator Final Review				
Investigator Final Review QA Representative Reviewed By:	赵, 琰	QA Representative Reviewed On:	2021.01.25 1	15:30
	赵, 琰 白, 亚磊	QA Representative Reviewed On: Investigator 1 Reviewed On:	2021.01.25 1 2021.01.25 1	
QA Representative Reviewed By:		·		
QA Representative Reviewed By: Investigator 1 Reviewed By:		Investigator 1 Reviewed On:		16:41
QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By:	白, 亚磊	Investigator 1 Reviewed On: Investigator 2 Reviewed On:	2021.01.25 1	16:41
QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By:	白, 亚磊	Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On:	2021.01.25 1	16:41
QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By:	白, 亚磊	Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On:	2021.01.25 1	16:41
QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By:	白, 亚磊	Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On:	2021.01.25 1	16:41
QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By:	白, 亚磊	Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On:	2021.01.25 1	16:41
QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By: Investigator 7 Reviewed By:	白, 亚磊	Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On: Investigator 7 Reviewed On:	2021.01.25 1	16:41
QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By: Investigator 7 Reviewed By: Investigator 7 Reviewed By: Investigator 8 Reviewed By:	白, 亚磊于, 芳	Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On: Investigator 7 Reviewed On:	2021.01.25 1	16:41
QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By: Investigator 7 Reviewed By: Investigator 7 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By:	白, 亚磊 于, 芳 邓, 献存	Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On: Investigator 7 Reviewed On: Investigator 8 Reviewed On:	2021.01.25 1	16:41 13:24 21:16
QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By: Investigator 7 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By: Department Final Approval Department Leader 1 Final Approved By:	白, 亚磊 于, 芳 邓, 献存 李, 云峰	Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On: Investigator 7 Reviewed On: Investigator 8 Reviewed On: Investigator 8 Reviewed On:	2021.01.25 1 2021.01.25 1 2021.01.25 2 2021.01.25 1	16:41 13:24 21:16 18:07
QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By: Investigator 7 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By: Department Final Approval Department Leader 1 Final Approved By: Department Leader 2 Final Approved By:	白, 亚磊 于, 芳 邓, 献存 李, 云峰 周, 凯松	Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On: Investigator 7 Reviewed On: Investigator 8 Reviewed On: Investigator 8 Reviewed On: Department Leader 1 Final Approved On: Department Leader 2 Final Approved On:	2021.01.25 1 2021.01.25 1 2021.01.25 2 2021.01.25 1 2021.01.25 1	21:16 18:07 16:48
QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By: Investigator 7 Reviewed By: Investigator 7 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By: Department Final Approval Department Leader 1 Final Approved By: Department Leader 2 Final Approved By: Department Leader 3 Final Approved By:	白, 亚磊 于, 芳 邓, 献存 李, 云峰 周, 凯松 Yeo, Chionkun	Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On: Investigator 7 Reviewed On: Investigator 8 Reviewed On: Investigator 8 Reviewed On: Department Leader 1 Final Approved On: Department Leader 2 Final Approved On: Department Leader 3 Final Approved On:	2021.01.25 1 2021.01.25 1 2021.01.25 2 2021.01.25 1 2021.01.25 1 2021.01.25 1	21:16 18:07 16:48
QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By: Investigator 7 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By: Department Final Approval Department Leader 1 Final Approved By: Department Leader 2 Final Approved By: Department Leader 3 Final Approved By: Department Leader 4 Final Approved By:	白, 亚磊 于, 芳 邓, 献存 李, 云峰 周, 凯松 Yeo, Chionkun	Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On: Investigator 7 Reviewed On: Investigator 8 Reviewed On: Investigator 8 Reviewed On: Department Leader 1 Final Approved On: Department Leader 2 Final Approved On: Department Leader 3 Final Approved On: Department Leader 4 Final Approved On:	2021.01.25 1 2021.01.25 1 2021.01.25 2 2021.01.25 1 2021.01.25 1 2021.01.25 1	21:16 18:07 16:48

This report was generated by 鹏云 徐 on 2021.06.17 08:23AM in Timezone GMT+08:00

Quality Approver 2 Final Approved By:

Quality Approver 2 Final Approved On:



PR#: 7956 Deviation No.:D-2020-0429

Record Status: Closed-Done

Quality Approver 3 Final Approved By: Quality Approver 3 Final Approved On:

Product Final Disposition						
Disposition Proposed By:	王, 怡菁	Disposition Proposed On:	2021.01.26 10:00			
Proposal Reviewed By: Proposal Reviewed On:						
Product Disposition Approved By:	管, 国兴	Product Disposition Approved On:	2021.01.26 10:11			